Guardant Health, Inc.
$90.8
▲
0.49%
2026-04-22 10:12:13
guardanthealth.com
NMS: GH
Explore Guardant Health, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$11.97 B
Current Price
$90.8
52W High / Low
$120.74 / $36.36
Stock P/E
—
Book Value
$-0.76
Dividend Yield
—
ROCE
-25.56%
ROE
348.42%
Face Value
—
EPS
$-3.32
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
2,490
Beta
1.65
Debt / Equity
-17.22
Current Ratio
4.84
Quick Ratio
4.56
Forward P/E
-126.02
Price / Sales
10.5
Enterprise Value
$10.82 B
EV / EBITDA
-27.28
EV / Revenue
11.02
Rating
Strong Buy
Target Price
$129.73
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Quest Diagnostics Incorporated | $200.41 | 22.15 | $22.16 B | 1.76% | 11.16% | 14.75% | $213.5 / $160.02 | $65.18 |
| 2. | Medpace Holdings, Inc. | $513.23 | 33.75 | $14.67 B | — | 84.68% | 70.23% | $628.92 / $250.05 | $16.18 |
| 3. | Castle Biosciences, Inc. | $25.16 | — | $744.77 M | — | -8.4% | -5.21% | $44.28 / $14.59 | $15.86 |
| 4. | IQVIA Holdings Inc. | $175.62 | 22.46 | $29.52 B | — | 10.59% | 21.44% | $247.05 / $134.65 | $38.34 |
| 5. | Precipio, Inc. | $28.15 | — | $50.21 M | — | -6.84% | -2.72% | $29.8 / $5.19 | $8.18 |
| 6. | IDEXX Laboratories, Inc. | $580.27 | 44.49 | $46.26 B | — | 61.76% | 66.2% | $769.98 / $402.85 | $20.14 |
| 7. | Myriad Genetics, Inc. | $5.14 | — | $484.84 M | — | -11.84% | -23.51% | $8.59 / $3.76 | $3.94 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 281.27 M | 265.2 M | 232.09 M | 203.47 M | 201.81 M |
| Operating Profit | -120.81 M | -98.99 M | -106.41 M | -111.04 M | -125.97 M |
| Net Profit | -128.49 M | -92.72 M | -99.9 M | -95.16 M | -111.01 M |
| EPS in Rs | -0.98 | -0.71 | -0.76 | -0.73 | -0.85 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 982.02 M | 739.02 M | 563.95 M | 449.54 M |
| Operating Profit | -437.25 M | -443.59 M | -564.73 M | -544.38 M |
| Net Profit | -416.28 M | -436.37 M | -479.45 M | -654.59 M |
| EPS in Rs | -3.17 | -3.33 | -3.66 | -4.99 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.01 B | 1.49 B | 1.79 B | 1.61 B |
| Total Liabilities | 2.11 B | 1.63 B | 1.63 B | 1.55 B |
| Equity | -99.31 M | -139.65 M | 158.68 M | 60.18 M |
| Current Assets | 1.47 B | 1.06 B | 1.35 B | 1.19 B |
| Current Liabilities | 302.73 M | 225.58 M | 205.92 M | 193.22 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -184.76 M | -239.86 M | -324.98 M | -309.46 M |
| Investing CF | -627.2 M | -261.31 M | 840.25 M | 149.82 M |
| Financing CF | 671.13 M | -1 M | 477.38 M | -189.09 M |
| Free CF | -233.07 M | -274.94 M | -345.46 M | -386.92 M |
| Capex | -48.31 M | -35.09 M | -20.49 M | -77.46 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 31.04% | 25.45% | — | — |
| Earnings Growth % | 8.98% | 26.76% | — | — |
| Profit Margin % | -59.05% | -85.02% | -145.61% | — |
| Operating Margin % | -60.02% | -100.14% | -121.1% | — |
| Gross Margin % | 60.79% | 59.74% | 65.23% | — |
| EBITDA Margin % | -52.79% | -76.83% | -136.79% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.